Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Technology Stocks : NASI (North American Scientific, Inc. -- Ignore unavailable to you. Want to Upgrade?

To: mantle7 who wrote (488)	3/22/1998 10:57:00 PM
From: THE BIG GB	Read Replies (1) \| Respond to of 658

NASI IS IN IT INFANCY AS FAR AS MARKETING THEIR PRODUCTS. MENTOR COULD BE ANOTHER MISSED OPPORTUNITY. IT IS CLEAR THAT NASI HAS SECURED TWO PARTNERS WITH AT LEASE A 5% STAKE IN THEM. MNTR & PRACSYS. PRACSYS IS BUILDING TWO LINEAR ACCELERATORS. ALSO LETS NOT FORGET RADIOMED A COMPANY NASI HAS A STAKE IN. NOW YOU TELL ME WHICH CO. YOU CHOOSE TO INVEST IN. GB

To: mantle7 who wrote (488)	3/23/1998 12:31:00 AM
From: BDR	Respond to of 658

<I would be curious to know what data you are relying on which indicates a peak in prostate cancer cases.> The CDC. The data is at this location but you will need Adobe Acrobat Reader to view the document which has some nice charts. cdc.gov An excerpt: "....The American Cancer Society (ACS) estimates that 184,000 new cases of prostate cancer will be diagnosed and that approximately 39,200 men will die of the disease in 1998.....From 1973 to 1992, the incidence of prostate cancer in the United States increased from 64 to 190 per 100,000 people, and the death rate rose by nearly 23%. More frequent use of new diagnostic methods such as blood testing may have contributed to this increase in the number of diagnosed cases. After the 1992 peak, the incidence of prostate cancer declined to 144 per 100,000 people in 1994." The article doesn't say why there is a decline but I believe it is a result of decreased emphasis on screening by the primary docs. I know that in my practice there was a dramatic decline in referrals for abnormal PSAs in 1992 that continues to this day. The encouraging piece of news is that cases are being diagnosed earlier at a potentially more curable stage and there is also apparently a slight decline in the death rate from the disease, though that is less clear at this time.